MXPA05006579A - Metodo para tratar el crecimiento de tejido angiogenico. - Google Patents

Metodo para tratar el crecimiento de tejido angiogenico.

Info

Publication number
MXPA05006579A
MXPA05006579A MXPA05006579A MXPA05006579A MXPA05006579A MX PA05006579 A MXPA05006579 A MX PA05006579A MX PA05006579 A MXPA05006579 A MX PA05006579A MX PA05006579 A MXPA05006579 A MX PA05006579A MX PA05006579 A MXPA05006579 A MX PA05006579A
Authority
MX
Mexico
Prior art keywords
tissue growth
angiogenic tissue
vesicle
treating angiogenic
treating
Prior art date
Application number
MXPA05006579A
Other languages
English (en)
Inventor
Francis J Martin
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA05006579A publication Critical patent/MXPA05006579A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un metodo para tratar una enfermedad o trastorno caracterizado por crecimiento de tejido angiogenico; el metodo incluye proveer una composicion de inmunoliposomas que comprende, lipidos que forman vesiculas que incluyen entre 1 y 20 por ciento en moles de un lipido que forma vesiculas derivatizado con un polimero hidrofilico, un ligando de eleccion de objetivo que tiene actividad biologica para promover angiogenesis, y un farmaco atrapado en dichos liposomas; y administrar la composicion de inmunoliposomas a un sujeto.
MXPA05006579A 2002-12-19 2003-12-19 Metodo para tratar el crecimiento de tejido angiogenico. MXPA05006579A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43511502P 2002-12-19 2002-12-19
US48814303P 2003-07-16 2003-07-16
PCT/US2003/041007 WO2004056323A2 (en) 2002-12-19 2003-12-19 Method of treating angiogenic tissue growth

Publications (1)

Publication Number Publication Date
MXPA05006579A true MXPA05006579A (es) 2005-12-14

Family

ID=32685367

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006579A MXPA05006579A (es) 2002-12-19 2003-12-19 Metodo para tratar el crecimiento de tejido angiogenico.

Country Status (9)

Country Link
US (1) US20040219204A1 (es)
EP (1) EP1587484A4 (es)
JP (1) JP2006517917A (es)
KR (1) KR20050090987A (es)
AU (1) AU2003300280A1 (es)
CA (1) CA2510780A1 (es)
MX (1) MXPA05006579A (es)
NO (1) NO20053397L (es)
WO (1) WO2004056323A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4715133B2 (ja) * 2004-08-26 2011-07-06 コニカミノルタエムジー株式会社 抗腫瘍リポソーム製剤およびその製造方法
JP2006151870A (ja) * 2004-11-29 2006-06-15 Olympus Corp 治療用ナノマシンおよび薬物送達システム
ES2526204T3 (es) * 2006-01-05 2015-01-08 Genentech, Inc. Anticuerpos anti-EphB4 y métodos para usar los mismos
WO2007130462A2 (en) * 2006-05-04 2007-11-15 Alza Corporation Treating micrometastases using immunoliposomes comprising a chemotherapeutic agent, a targeting ligand and a hydrophilic polymer
US8753673B2 (en) * 2006-05-23 2014-06-17 Taiwan Liposome Co. Ltd. Liposome composition for delivery of a therapeutic agent to eyes
JP5072275B2 (ja) * 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
US8352000B2 (en) * 2006-08-22 2013-01-08 Samsung Electronics Co., Ltd. Mobile phone having dual connection member and hinge device thereof
US20080070855A1 (en) * 2006-09-20 2008-03-20 James Pitzer Gills Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
JPWO2009125858A1 (ja) * 2008-04-07 2011-08-04 静岡県公立大学法人 ２−インドリノン誘導体を含有する脂質分散体製剤
WO2020154746A1 (en) * 2019-01-25 2020-07-30 Mantra Bio, Inc. Skeletal muscle targeting moieties and uses thereof
CA3165930A1 (en) 2020-01-27 2021-08-05 Terry GAIGE Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
AU6989094A (en) * 1993-05-27 1994-12-20 Entremed, Inc Compositions and methods for treating cancer and hyperproliferative disorders
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
CN1202932A (zh) * 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
AU714992B2 (en) * 1996-08-23 2000-01-13 Alza Corporation Liposomes containing a cisplatin compound
EP0932390A1 (en) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6224903B1 (en) * 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
JP2001510808A (ja) * 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
CA2353593A1 (en) * 1998-12-18 2000-06-22 Hadasit Medical Research Services & Development Ltd. Method of administering a compound to multi-drug resistant cells
WO2002078672A2 (en) * 2001-03-30 2002-10-10 Alza Corporation Liposomal tumor necrosis factor compositions and methods

Also Published As

Publication number Publication date
JP2006517917A (ja) 2006-08-03
EP1587484A4 (en) 2008-11-12
WO2004056323A3 (en) 2006-05-11
AU2003300280A1 (en) 2004-07-14
NO20053397L (no) 2005-07-13
WO2004056323A2 (en) 2004-07-08
CA2510780A1 (en) 2004-07-08
KR20050090987A (ko) 2005-09-14
EP1587484A2 (en) 2005-10-26
US20040219204A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
US20220176147A1 (en) Wearable Micro-LED Healing Bandage
NO20053397L (no) Fremgangsmate for behandling av angiogen vevsvekst.
KR101236363B1 (ko) 연조직 증강을 위한 입자
Vaage et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes
ATE152614T1 (de) Mittel zur behandlung entzündeter gewebe
DE60044464D1 (de) Bukkale transmukosale arzneidarreichung unter verwendung einer festen lösung
US20110033437A1 (en) Debridement Method Using Topical Nitric Oxide Donor Devices and Compositions
NZ336511A (en) Treating prostatic diseases using delayed and/or sustained release formulations of activated vitamin D
US8754045B2 (en) Enzymatic debridement therapy for abnormal cell proliferation
ES2092296T3 (es) Metodo de tratamiento de tejidos infectados.
NZ528523A (en) Liposome composition for improved intracellular delivery of a therapeutic agent
CA2184242A1 (en) Drug Targeting System, Method for Preparing Same and Its Use
AUPN531195A0 (en) Lipid extract having anti-inflamatory activity
WO2001091728A3 (en) Nanoemulsion formulations
Lerch et al. Bacteria ingestion by blowfly larvae: an in vitro study
US20220249668A1 (en) Drug transdermal delivery system
US20120237612A1 (en) Ultrasound Gel And Methods Of Manufacturing Same
WO2003057162A3 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
Stewart et al. Treatment of ocular squamous cell carcinomas in cattle with interleukin‐2
KR20180105115A (ko) 타우로리딘의 피부-침투성 제제
TRAFNY et al. Anti-pseudomonal activity of collagen sponge with liposomal polymyxin B
SE0301577D0 (sv) Low sodium solution
CN209033278U (zh) 一种烧烫伤修复用生物膜
ES2524444T3 (es) Método para preparar una lámina de fibrina sólida
Lerchenmüller et al. Rhinocerebral zygomycosis in a patient with acute lymphoblastic leukemia